Clinical Practice Guidelines on Hepatitis Delta Virus.

[1]  A. Berger,et al.  A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. , 2023, The New England journal of medicine.

[2]  F. Tacke,et al.  Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries. , 2023, Journal of hepatology.

[3]  G. Tisone,et al.  Successful clinical and virological outcomes of liver transplantation for HDV/HBV‐related disease after long‐term discontinuation of hepatitis B immunoglobulins , 2023, Clinical transplantation.

[4]  B. Maasoumy,et al.  Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA , 2023, Journal of viral hepatitis.

[5]  F. Tacke,et al.  Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. , 2023, JHEP reports : innovation in hepatology.

[6]  H. Dahari,et al.  Treatment of chronic hepatitis D with peginterferon lambda—the phase 2 LIMT-1 clinical trial , 2023, Hepatology.

[7]  R. Idilman,et al.  Non‐invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta , 2023, Journal of viral hepatitis.

[8]  A. Mocroft,et al.  Hepatitis delta infection among persons living with HIV in Europe , 2023, Liver international : official journal of the International Association for the Study of the Liver.

[9]  F. Zoulim,et al.  A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics. , 2023, Journal of hepatology.

[10]  M. Dandri,et al.  Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 , 2023, 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.

[11]  T. Volz,et al.  Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment , 2023, JHEP reports : innovation in hepatology.

[12]  A. Dinani,et al.  The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection , 2022, Journal of viral hepatitis.

[13]  W. Haefeli,et al.  Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide—An Exploratory Phase I Clinical Trial , 2022, International journal of molecular sciences.

[14]  T. Asselah,et al.  Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. , 2022, The New England journal of medicine.

[15]  M. Brunetto,et al.  Highly dynamic changes of regional HBV epidemiology over two decades. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  D. Kleiner,et al.  Shear wave elastography: How well does it perform in chronic hepatitis D virus infection? , 2022, Journal of Viral Hepatitis.

[17]  W. Haefeli,et al.  Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. , 2022, The Lancet. Infectious diseases.

[18]  F. Tacke,et al.  Real‐life experiences with bulevirtide for the treatment of hepatitis delta—48 weeks data from a German centre , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[19]  D. Roulot,et al.  Hepatitis delta virus reflex testing in patients with hepatitis B improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France , 2022, Journal of Hepatology.

[20]  M. Buti,et al.  Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D , 2022, JHEP reports : innovation in hepatology.

[21]  M. Biermer,et al.  Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. , 2022, Journal of hepatology.

[22]  H. Wedemeyer,et al.  T‐cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[23]  P. Lampertico,et al.  BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. , 2022, Journal of hepatology.

[24]  S. Iwata,et al.  Structure of the bile acid transporter and HBV receptor NTCP , 2022, Nature.

[25]  M. Muramatsu,et al.  Structural insights into the HBV receptor and bile acid transporter NTCP , 2022, Nature.

[26]  M. Trauner,et al.  Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study , 2022, Alimentary pharmacology & therapeutics.

[27]  R. Bartenschlager,et al.  Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. , 2022, Journal of hepatology.

[28]  J. Wiegand,et al.  Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection , 2022, Pathogens.

[29]  M. Rizzetto,et al.  Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients , 2022, Transplantation.

[30]  G. Papatheodoridis,et al.  Hepatocellular carcinoma: the virus or the liver? , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[31]  T. Reiberger,et al.  Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis. , 2022, Journal of hepatology.

[32]  C. Coffin,et al.  Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada , 2022, JHEP reports : innovation in hepatology.

[33]  M. Buti,et al.  Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability , 2022, Viruses.

[34]  R. Idilman,et al.  A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis , 2021, Hepatology.

[35]  H. Yoshiji,et al.  Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.

[36]  H. Wedemeyer,et al.  New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. , 2021, Clinics in liver disease.

[37]  F. Zoulim,et al.  Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. , 2021, Journal of hepatology.

[38]  M. Manns,et al.  HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta , 2021, Hepatology communications.

[39]  A. Lee,et al.  Hepatitis D Review: Challenges for the Resource-Poor Setting , 2021, Viruses.

[40]  R. Idilman,et al.  Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. , 2021, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[41]  S. Ciesek,et al.  Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. , 2021, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[42]  A. Duberg,et al.  Risk of hepatocellular carcinoma in hepatitis B and D virus co‐infected patients: A systematic review and meta‐analysis of longitudinal studies , 2021, Journal of viral hepatitis.

[43]  M. Buti,et al.  2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation , 2021, Alimentary pharmacology & therapeutics.

[44]  R. L. Harrison,et al.  Changes to virus taxonomy and to the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2021) , 2021, Archives of Virology.

[45]  M. Buti,et al.  One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease , 2021, Alimentary pharmacology & therapeutics.

[46]  F. Cosset,et al.  HDV-Like Viruses , 2021, Viruses.

[47]  Marilou H. Barrios,et al.  Hepatitis Delta Virus (HDV) and Delta-Like Agents: Insights Into Their Origin , 2021, Frontiers in Microbiology.

[48]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[49]  G. Papatheodoridis,et al.  Is hepatitis delta underestimated? , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[50]  J. Hoofnagle,et al.  Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy , 2021, Alimentary pharmacology & therapeutics.

[51]  M. Yuen,et al.  Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B , 2021, Hepatology.

[52]  T. Asselah,et al.  Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[53]  P. Farci,et al.  Hepatitis D Virus and Hepatocellular Carcinoma , 2021, Viruses.

[54]  J. Pratschke,et al.  Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection , 2021, Viruses.

[55]  Ming‐Lung Yu,et al.  Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues , 2021, Scientific Reports.

[56]  E. Cholongitas,et al.  Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[57]  M. Rizzetto,et al.  The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease , 2021, Journal of advanced research.

[58]  S. Hamid,et al.  The changing scenario of hepatitis D. , 2021, Journal of hepatology.

[59]  W. Almawi,et al.  Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: a meta-analysis. , 2020, Antiviral research.

[60]  M. Bazinet,et al.  Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139‐Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection , 2020, Hepatology communications.

[61]  S. Hamid,et al.  The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[62]  D. Kleiner,et al.  Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? , 2020, The American journal of gastroenterology.

[63]  Z. Abbas,et al.  The Severity of Hepatitis D in Young Adults of Age 18-25 Years , 2020, Cureus.

[64]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[65]  J. Glenn,et al.  High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis among Mongols in Southern California , 2020, Digestive Diseases and Sciences.

[66]  M. Manns,et al.  Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[67]  M. Manns,et al.  Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta , 2020, Journal of viral hepatitis.

[68]  F. Roudot-thoraval,et al.  Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta. , 2020, Journal of hepatology.

[69]  M. Blanchet,et al.  Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro. , 2020, Antiviral research.

[70]  Celal Ulaşoğlu,et al.  A case of autoimmune hepatitis following pegylated interferon treatment of chronic hepatitis delta , 2020, Northern clinics of Istanbul.

[71]  H. Wedemeyer,et al.  Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. , 2020, The American journal of tropical medicine and hygiene.

[72]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[73]  O. Weiland,et al.  Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes , 2020, Hepatology.

[74]  F. Negro,et al.  Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2020, Journal of hepatology.

[75]  K. Agarwal,et al.  Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. , 2020, Journal of hepatology.

[76]  D. Kleiner,et al.  The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D. , 2019, Antiviral research.

[77]  M. Peppelenbosch,et al.  Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection , 2019, The Journal of infectious diseases.

[78]  D. Kleiner,et al.  Vibration‐controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection , 2019, Journal of viral hepatitis.

[79]  M. Buti,et al.  Long‐term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia , 2019, Alimentary pharmacology & therapeutics.

[80]  F. Zoulim,et al.  Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.

[81]  D. Boon,et al.  Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  F. Zoulim,et al.  Non‐F HBV/HDV‐3 coinfection is associated with severe liver disease in Western Brazilian Amazon , 2019, Journal of medical virology.

[83]  C. Yurdaydın.  New treatment options for delta virus: Is a cure in sight? , 2019, Journal of viral hepatitis.

[84]  S. Alavian,et al.  Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level , 2019, Gastroenterology.

[85]  M. Buti,et al.  Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. , 2019, Journal of hepatology.

[86]  J. Sidney,et al.  Hepatitis D Virus-Specific CD8+ T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection. , 2019, Gastroenterology.

[87]  W. Haefeli,et al.  GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection , 2019, Journal of Hepatology.

[88]  T. Santantonio,et al.  Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long‐term tenofovir or entecavir , 2019, Alimentary pharmacology & therapeutics.

[89]  M. Manns,et al.  Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. , 2019, The Lancet. Infectious diseases.

[90]  F. Tacke,et al.  Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. , 2019, Journal of hepatology.

[91]  K. Zieniewicz,et al.  2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50‐year evolution of liver transplantation , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[92]  H. Goyal,et al.  Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis , 2018, Gut.

[93]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[94]  L. Gheorghe,et al.  Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection , 2018, Journal of viral hepatitis.

[95]  M. Hiet,et al.  Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. , 2018, Journal of hepatology.

[96]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[97]  M. Emmert-Buck,et al.  Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma , 2018, Molecular Cancer Research.

[98]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[99]  M. Manns,et al.  Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: The Hepatitis Delta International Network (HDIN) , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[100]  W. Haefeli,et al.  Drug–Drug Interaction Potential of the HBV and HDV Entry Inhibitor Myrcludex B Assessed in vitro , 2018, Antiviral therapy.

[101]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[102]  R. Idilman,et al.  Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study , 2018, Hepatology.

[103]  R. Idilman,et al.  Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease , 2018, The Journal of infectious diseases.

[104]  H. Wedemeyer,et al.  Development and performance of prototype serologic and molecular tests for hepatitis delta infection , 2018, Scientific Reports.

[105]  W. Haefeli,et al.  The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics , 2018, Clinical pharmacology and therapeutics.

[106]  A. Lohse,et al.  Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo , 2017, Gut.

[107]  P. Schmid,et al.  Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. , 2017, The lancet. Gastroenterology & hepatology.

[108]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[109]  H. Günthard,et al.  Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[110]  N. Heaton,et al.  Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[111]  M. Manns,et al.  Non‐invasive fibrosis score for hepatitis delta , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[112]  M. Manns,et al.  Antiviral treatment and liver‐related complications in hepatitis delta , 2017, Hepatology.

[113]  H. Günthard,et al.  Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. , 2017, Journal of hepatology.

[114]  L. Caccamo.  Long‐term nucleos(t)ide analog(s) monoprophylaxis in Delta coinfected liver transplant recipients , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[115]  J. Hoofnagle,et al.  Noninvasive markers for staging fibrosis in chronic delta hepatitis , 2017, Alimentary pharmacology & therapeutics.

[116]  E. Cholongitas,et al.  Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[117]  Thorsten Lehr,et al.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. , 2016, Journal of hepatology.

[118]  S. Chevret,et al.  First international external quality assessment for hepatitis delta virus RNA quantification in plasma , 2016, Hepatology.

[119]  O. Fatih,et al.  Hepatitis B Virus and Hepatitis D Virus Recurrence in Patients Undergoing Liver Transplantation for Hepatitis B Virus and Hepatitis B Virus Plus Hepatitis D Virus. , 2016, Transplantation proceedings.

[120]  A. Andriulli,et al.  HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response , 2016, Alimentary pharmacology & therapeutics.

[121]  Z. Abbas,et al.  Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial. , 2016, World journal of hepatology.

[122]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[123]  M. Manns,et al.  Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[124]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[125]  Johnm . Taylor.  Hepatitis D Virus Replication. , 2015, Cold Spring Harbor perspectives in medicine.

[126]  M. Conti,et al.  Can Antiretroviral Therapy Modify the Clinical Course of HDV Infection in HIV-Positive Patients? , 2015, Antiviral therapy.

[127]  F. Cambra,et al.  Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[128]  M. Serper,et al.  Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. , 2015, Journal of hepatology.

[129]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[130]  M. Haberal,et al.  Hepatitis B- and hepatitis D-virus-related liver transplant: single-center data. , 2015, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[131]  H. Waterham,et al.  Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype , 2015, Hepatology.

[132]  Peter Schmid,et al.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling , 2014, Hepatology.

[133]  V. Soriano,et al.  Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients , 2014, AIDS.

[134]  M. Manns,et al.  Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta , 2014, PloS one.

[135]  M. Manns,et al.  Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta , 2014, Hepatology.

[136]  J. Hoofnagle,et al.  Long‐term therapy of chronic delta hepatitis with peginterferon alfa , 2014, Alimentary pharmacology & therapeutics.

[137]  M. Manns,et al.  Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals , 2014, Gut.

[138]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[139]  M. Manns,et al.  Development and evaluation of a baseline-event-anticipation score for hepatitis delta , 2014, Journal of viral hepatitis.

[140]  G. Casazza,et al.  High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta , 2014, PloS one.

[141]  C. Delaugerre,et al.  Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. , 2013, AIDS research and human retroviruses.

[142]  G. Touloumi,et al.  Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. , 2013, Journal of hepatology.

[143]  S. Chevret,et al.  Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[144]  A. Lohse,et al.  The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. , 2013, Journal of hepatology.

[145]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[146]  D. Kremsdorf,et al.  Large hepatitis delta antigen activates STAT‐3 and NF‐κB via oxidative stress , 2012, Journal of viral hepatitis.

[147]  R. Idilman,et al.  Entecavir treatment of chronic hepatitis D. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[148]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[149]  S. Sebti,et al.  Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.

[150]  R. Groszmann,et al.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.

[151]  M. Manns,et al.  Peginterferon plus adefovir versus either drug alone for hepatitis delta. , 2011, The New England journal of medicine.

[152]  A. Andriulli,et al.  Outcome of chronic delta hepatitis in Italy: a long-term cohort study. , 2010, Journal of hepatology.

[153]  R. Idilman,et al.  Natural history and treatment of chronic delta hepatitis , 2010, Journal of viral hepatitis.

[154]  A. Alibrandi,et al.  Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses , 2010, Journal of Virology.

[155]  G. Iconomou,et al.  Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). , 2010, Annals of hepatology.

[156]  S. Kotenko,et al.  Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[157]  Z. Abbas,et al.  Interferon alpha for chronic hepatitis D. , 2010, The Cochrane database of systematic reviews.

[158]  M. Buti,et al.  Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. , 2010, Journal of hepatology.

[159]  M. Manns,et al.  Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[160]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[161]  C. Yurdaydın,et al.  Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon , 2008, Journal of viral hepatitis.

[162]  T. Michiels,et al.  IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo , 2008, PLoS pathogens.

[163]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[164]  C. Toro,et al.  Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients? , 2008, Antiviral therapy.

[165]  C. Yurdaydın,et al.  A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis , 2007, Journal of viral hepatitis.

[166]  P. Reggiani,et al.  Role of Lamivudine in the Posttransplant Prophylaxis of Chronic Hepatitis B Virus and Hepatitis Delta Virus Coinfection , 2007, Transplantation.

[167]  R. Sacco,et al.  Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases , 2007, Journal of viral hepatitis.

[168]  E. Nicolas,et al.  Assembly of Hepatitis Delta Virus: Particle Characterization, Including the Ability To Infect Primary Human Hepatocytes , 2007, Journal of Virology.

[169]  M. Mizokami,et al.  High frequency of hepatocellular carcinoma in Mongolia; association with mono‐, or Co‐infection with hepatitis C, B, and delta viruses , 2006, Journal of medical virology.

[170]  A. Andriulli,et al.  Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta , 2006, Hepatology.

[171]  Shou-Dong Lee,et al.  Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. , 2006, Gastroenterology.

[172]  N. Sut,et al.  Efficacy of interferon α‐2b and lamivudine combination treatment in comparison to interferon α‐2b alone in chronic delta hepatitis: A randomized trial , 2006 .

[173]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[174]  P. Pontisso,et al.  Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients , 2006, Hepatology.

[175]  L. Gheorghe,et al.  Natural history of compensated viral B and D cirrhosis. , 2005, Romanian journal of gastroenterology.

[176]  M. Manns,et al.  Lamivudine therapy in chronic delta hepatitis: a multicentre randomized‐controlled pilot study , 2005, Alimentary pharmacology & therapeutics.

[177]  U. Akarca,et al.  Two-Year Interferon Therapy with Or without Ribavirin in Chronic Delta Hepatitis , 2005, Antiviral therapy.

[178]  K. Demır,et al.  Alpha Interferon and Ribavirin Combination Therapy of Chronic Hepatitis D , 2005, Antimicrobial Agents and Chemotherapy.

[179]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.

[180]  M. Manns,et al.  Famciclovir treatment of chronic delta hepatitis. , 2002, Journal of hepatology.

[181]  R. D. de Man,et al.  Lamivudine–high dose interferon combination therapy for chronic hepatitis B patients co‐infected with the hepatitis D virus , 2000 .

[182]  A. Andriulli,et al.  Changing pattern of chronic hepatitis D in Southern Europe. , 1999, Gastroenterology.

[183]  C. Hourioux,et al.  Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains. , 1998, The Journal of general virology.

[184]  R. Tukey,et al.  Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. , 1996, Gastroenterology.

[185]  F. Callea,et al.  Long‐term interferon‐α treatment of children with chronic hepatitis delta: a multicentre study , 1996 .

[186]  Brenda L. Bass,et al.  RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase , 1996, Nature.

[187]  P. Casey,et al.  The Hepatitis Delta Virus Large Antigen Is Farnesylated Both in Vitro and in Animal Cells (*) , 1996, The Journal of Biological Chemistry.

[188]  Y. Liaw.  Role of hepatitis C virus in dual and triple hepatitis virus infection , 1995, Hepatology.

[189]  W. Sheng,et al.  Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. , 1995, Gastroenterology.

[190]  D. Mathieu,et al.  Long‐term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis , 1995, Hepatology.

[191]  J. Crespo,et al.  Correlation between hepatitis B viremia and the clinical and histological activity of chronic delta hepatitis , 1994, Medical Microbiology and Immunology.

[192]  P. Meier,et al.  Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. , 1994, The Journal of clinical investigation.

[193]  P. van Eyken,et al.  Treatment of chronic hepatitis D with interferon alfa-2a. , 1994, The New England journal of medicine.

[194]  M. Rizzetto,et al.  Recurrence of hepatitis D (delta) in liver transplants: histopathological aspects. , 1993, Gastroenterology.

[195]  Y. Ilan,et al.  Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells. , 1992, The Journal of infectious diseases.

[196]  R. Merion,et al.  Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. , 1992, Gut.

[197]  J. Glenn,et al.  Identification of a prenylation site in delta virus large antigen. , 1992, Science.

[198]  M. Rizzetto,et al.  Patterns of hepatitis delta virus reinfection and disease in liver transplantation. , 1991, Gastroenterology.

[199]  M. Brunetto,et al.  Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D , 1991, Hepatology.

[200]  M. Moroni,et al.  Incidence of hepatitis delta virus infection in acute HBsAg-negative hepatitis. , 1989, The Journal of infectious diseases.

[201]  G. Fattovich,et al.  Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. , 1987, The Journal of infectious diseases.

[202]  R. Purcell,et al.  Type D hepatitis: The clinical significance of hepatitis D virus RNA in serum as detected by a hybridization‐based assay , 1986, Hepatology.

[203]  M. Buti,et al.  Serological diagnosis of acute delta hepatitis , 1986, Journal of medical virology.

[204]  N. Caporaso,et al.  Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. , 1983, Gastroenterology.

[205]  M. Rizzetto,et al.  Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. , 1983, Annals of internal medicine.

[206]  D. Vergani,et al.  INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B , 1982, The Lancet.

[207]  M. Yuen,et al.  Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients , 2020, Journal of Hepatology.

[208]  E. Rigopoulou,et al.  Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. , 2013, Annals of hepatology.

[209]  M. Manns,et al.  Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. , 2012, The Turkish Journal of Gastroenterology.

[210]  M. Manns,et al.  Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. , 2012, Journal of hepatology.

[211]  B. Stieger.  The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. , 2011, Handbook of experimental pharmacology.

[212]  D. Samuel,et al.  Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation. , 1993, Archives of virology. Supplementum.

[213]  M. Brunetto,et al.  Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. , 1987, Journal of hepatology.

[214]  F. Negro,et al.  Microsomal autoantibodies in chronic infections with HBsAg associated delta agent , 1983 .